Titre :

Budesonide transnasal pulsating nebulization after surgery in chronic rhinosinusitis with nasal polyps

Auteur(s) :

Bourhis, Thomas [Auteur]
Mouawad, Francois [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Szymanski, Claire [Auteur]
Mortuaire, Geoffrey [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]

Titre de la revue :

Drug Delivery and Translational Research

Nom court de la revue :

Drug Deliv Transl Res

Numéro :

12

Pagination :

925–930

Date de publication :

2022-04

ISSN :

2190-3948

Mot(s)-clé(s) :

Nasal polyps
Tissue remodeling
Transnasal nebulization
Budesonide
Schronic rhinosinusitis
Sinus surgery

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Intranasal corticosteroid drugs are widely used in chronic rhinosinusitis with nasal polyps (CRSwNP). In contrast to classical delivery with nasal pump sprays, pulsating aerosols can deliver significant doses into superior ...
Lire la suite >Intranasal corticosteroid drugs are widely used in chronic rhinosinusitis with nasal polyps (CRSwNP). In contrast to classical delivery with nasal pump sprays, pulsating aerosols can deliver significant doses into superior and posterior sinonasal spaces. A case-control study was designed to assess the efficacy of corticosteroid transnasal nebulization on short-term mucosal recovery and quality of life (QoL) following endoscopic sinus surgery in CRSwNP. Thirty patients were prospectively enrolled to receive either 1-month budesonide nasal pump spray or 1-month budesonide 100-Hz acoustic pulsating nebulization at the first postoperative visit (day 8). Patients were evaluated with Lund-Kennedy endoscopic score at day 8 (D8) and 1 month later (M1). CRS-related QoL questionnaires (SNOT22 and RhinoQOL) were fulfilled at M1. The Lund-Kennedy endoscopic scores compared between D8 and M1 were suggestively improved in the group treated with budesonide nebulization (mean difference between groups, - 18.28 units; 95%CI, - 31.29 to - 5.28 units, p = 0.014). QoL measurements were comparable at M1 between the groups of patients. No unexpected adverse event was described with both budesonide delivery protocols. In the early postoperative period, patients with CRswNP may benefit from pulsating nebulization. Large studies should be conducted to confirm the results. Safety profile related to systemic steroid absorption and bioavailability in chronic respiratory diseases also need to be addressed for further use.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CNRS
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290

Date de dépôt :

2021-07-06T12:44:29Z
2024-01-09T09:17:17Z